You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
Software for Determining Proteoform Heterogeneity and Protein Expression Fidelity
SBC: GENNEXT TECHNOLOGIES, INC. Topic: 400The importance of large protein drugsbiopharmaceuticalsand their generic counterpartsknown as biosimilarshas created a need for improved analytics to facilitate biopharmaceutical research and to combat adverse drug reactionsThe recombinant protein expression process is inherently prone to low level errors resulting in sequence variants caused by amino acid misincorporationwhich are observed in bot ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
The Point Digit: A ratcheting prosthetic finger using advanced rapid manufacturing technology
SBC: POINT DESIGNS, LLC Topic: NICHDThe Point DigitA Ratcheting Prosthetic Finger UsingAdvanced Rapid Manufacturing Technology Project SummaryAbstract The goal of the proposed project is to develop and commercialize a purely mechanicalratcheting prosthetic fingerthe Point Digitwhichhas an industry leading strength to weight ratiocan be operated unilaterallyone handedoffers anatomical rotation and flexion around the patient s metacar ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
A Portable Device for Accurate Mouse Tail Vein Injection
SBC: Technology Commercialization Partners LLC Topic: ODPROJECT SUMMARYABSTRACT To datethe standard method to access a mouse tail vein is manual injectionbut its yield rate is poor in generalThis leads to multiple needle insertions associated with tissue damage and painBesidesfailure in tail vein injection leads to data lossand thereby more animals will be required to compensate itFinallythe dose variation induced by unreliable injection increases erro ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Integrated Microbial Screening and Antimicrobial Susceptibility Test on Microfluidic Digital Array for Diagnosis of Urinary Tract Infections
SBC: Combinati Incorporated Topic: NIAIDAbstract COMBiNATi will work with Stanford University to bring the world s first integrated ID AST UTI diagnostic platform to the market by combining COMBiNATi sone clickcost effective dPCR platform with Stanford s pathogen identificationIDHRMA algorithm for broad detectiondeep characterization and absolute quantification of UTI pathogensBy the end of the Phaseprojectwe will deliver the prototype ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Evolution of an Adaptable Prosthetic Foot Design for Normalization of Biomechanics During Community Participation
SBC: OHIO WILLOW WOOD COMPANY, THE Topic: NICHDEvolution of an Adaptable Prosthetic Foot Design for Normalization ofBiomechanics During Community Participation Summary/AbstractThe vision of this project is to improve the functional physical mobility of people with lower extremity amputations especially on uneven ground, side-slopes or when foot placement varies from side-to-side. People with amputations will be enabled to confidently participa ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Biosensor and Eyedrop Bottle Technologies for Glaucoma Adherence Monitoring
SBC: Toromedes, Inc Topic: NEIProject SummaryNon adherence with prescribed systemic drugs leads to poor outcomes and increases the cost of healthcareGlaucomathe leading cause of irreversible blindnessaffects more thanmillion people worldwideLowering intraocular pressurethe only proven method of delaying both the development and progression of glaucomais typically done with topical administration of eye dropswhich has notorious ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
High-Throughput Assay for Profiling Alternative Splicing and Splicing Regulators
SBC: Biospyder Technologies, Inc. Topic: 172SummaryThis Phase I program will develop TempO Splicea highly multiplexed targeted sequencing assay monitoring RNA Binding ProteinRBPsplicing expression and alternatively splicedASmRNA representatives of coregulated splicing modulesa novel variation of the TempO Seqassay used for high throughput screeningdesigned to address the hypothesis that it is possible to provide a surrogate assay of the who ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Developing an efficient E-cigarette aerosol generation and exposure system for rodent models with aerosol characteristics equivalent to those inhaled by E-cigarette users
SBC: AUTOMATE SCIENTIFIC, INC. Topic: NIDAAbstract E cigarettes (E-cigs) are increasingly popular worldwide, in particular, among youths. E-cigs may contribute to nicotine addiction and are unlikely to discourage conventional cigarette smoking. Mainstream and second-hand E-cig aerosols contain, in addition to nicotine, detectable levels of toxins including carcinogens and heavy metals such as formaldehyde, benzene, nitrosamines, cadmium a ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Pharmacologic Suppression of Reperfusion Injury Following Endovascular Thrombectomy In Stroke.
SBC: BIOMIMETIX JV LLC Topic: 102Ischemic stroke is a leading cause of death and disability in the United States. This often is attributable to thrombus formation at an atherosclerotic plaque or thromboembolism. Patients who present within 4.5 hours of symptom onset are eligible for thrombolysis with tissue plasminogen activator (tPA). This serves andlt;5% of victims. Recently, major advance has been made with proven efficacy fro ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Evaluation of therapeutic efficacy and safety of novel small RNA target delivery platform in vivo.
SBC: Oncoimmune Inc Topic: 100Project Summary AbstractThe recent rapid expansion of genomic data greatly contributes to the understanding of disease development and progressionTo translate these genetic discoveries into clinical applicationswe need to develop therapeutic platforms that can specifically modulate the expression of disease related genes in vivoSmall RNAssuch as microRNAs and siRNAs function in messenger RNA silen ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health